eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

Pure Biologics movie – immunotherapeutic portfolio

12 November

2020

Pure Biologics movie – immunotherapeutic portfolio

Watch a video about the most advanced projects targeting colon cancer, non-small cell lung cancer and triple-negative breast cancer.

Antibody E-Conference 13.10.2020 – invitation

10 November

2020

Antibody E-Conference 13.10.2020 – invitation

Pure Biologics antibody e-conference on November 13, 2020, 13:00!

Project PB001 – partner for preclinical research

5 November

2020

Project PB001 – partner for preclinical research

We chose a partner to carry out the first panel of preclinical studies in the PB001 project.

5 November

2020

Pure Biologics – new webpage!

The PB010 PureSelect2 project has been successfully completed!

30 October

2020

The PB010 PureSelect2 project has been successfully completed!

The aim was to develop an improved platform for the selection and production of antibody fragments.

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

18 December

2023

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

23 November

2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020